title: Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis.
abstract: Thyroid autoimmunity and dysfunction are a well known side effect of IFN alpha therapy for viral hepatitis and tumors, while the IFN beta effects on the thyroid gland in neurological patients have not been studied. The aim of this longitudinal study was to look for the appearance of thyroid autoimmunity as well as for the occurrence of overt thyroid disease in the patients affected by multiple sclerosis (MS) treated with IFN beta 1b. Eight patients (4 males, 4 females) undergoing r-IFN beta 1b treatment (8 M.U. every other day for 9 months) for relapsing remitting multiple sclerosis entered the study. We have analyzed thyroid function parameters and auto antibody levels before and after 1, 2, 3, 6 and 9 months of therapy. None of them referred to familiar thyroid pathology or presented clinically overt thyroid disease except for one patient (case 4) who showed TPO-Ab pretreatment positivity and another (case 8) who was in therapy with Levothyroxine 100 microg/die for multinodular goiter. The number of patients with appearance of thyroid antibodies has slowly increased, until the third month of therapy with 3 patients out of 7 positive for TPO-Ab. The only case of overt thyroid dysfunction reported by us appeared after nine months of therapy and consisted of a hypothyroidism. Our data suggest that short-term interferon beta treatment is able to induce thyroid autoimmunity (42.8%) and dysfunction (12.5%).
authors.affiliation: Institute of Endocrinology, II University of Napoli, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Rotondi
authors.forename: A
authors.initials: A
authors.lastname: Oliviero
authors.forename: P
authors.initials: P
authors.lastname: Profice
authors.forename: C M
authors.initials: CM
authors.lastname: Mone
authors.forename: B
authors.initials: B
authors.lastname: Biondi
authors.forename: A
authors.initials: A
authors.lastname: Del Buono
authors.forename: G
authors.initials: G
authors.lastname: Mazziotti
authors.forename: A M
authors.initials: AM
authors.lastname: Sinisi
authors.forename: A
authors.initials: A
authors.lastname: Bellastella
authors.forename: C
authors.initials: C
authors.lastname: Carella
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000139:chemically induced; D015551:Autoimmunity; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000009:adverse effects* / Q000627:therapeutic use; D007453:Iodide Peroxidase / Q000276:immunology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000628:therapy*; D013954:Thyroglobulin / Q000276:immunology; D013959:Thyroid Diseases / Q000139:chemically induced / Q000276:immunology; D013961:Thyroid Gland / Q000276:immunology*; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood